Research location

Fuzhou

Fujian, China

Published trials423

Site observations511

Linked trials published423

Page1 / 9

Research activity in Fuzhou

Fujian, China

CureCurrent currently publishes aggregate city-level research activity for this location: 423 trials and 511 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Fuzhou

423 linked trials · page 1 of 9

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10 · 1 site observation

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/ObesityNCT07747857 · 2026-08-25 · 1 site observation

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart DiseaseNCT07214376 · 2026-08-21 · 1 site observation

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT07622186 · 2026-07-15 · 1 site observation

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerNCT07476287 · 2026-07-02 · 1 site observation

Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUreNCT07687186 · 2026-06-22 · 1 site observation

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNCT07517042 · 2026-06-10 · 1 site observation

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast CancerNCT07702708 · 2026-06-01 · 2 site observations

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerNCT06993506 · 2026-05-28 · 1 site observation

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 3 site observations

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.NCT07593027 · 2026-04-30 · 1 site observation

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate CancerNCT07562438 · 2026-04-29 · 1 site observation

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.NCT07450599 · 2026-04-27 · 1 site observation

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLCNCT07541521 · 2026-04-13 · 1 site observation

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)NCT07416474 · 2026-04-03 · 2 site observations

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)NCT07431827 · 2026-03-18 · 2 site observations

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 1 site observation

HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure ManagementNCT07402239 · 2026-03-16 · 1 site observation

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLCNCT07528066 · 2026-03-02 · 1 site observation

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersNCT07227298 · 2026-01-30 · 1 site observation

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)NCT07227597 · 2026-01-29 · 1 site observation

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyNCT07581834 · 2026-01-21 · 1 site observation

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)NCT07320105 · 2026-01-15 · 1 site observation

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02 · 1 site observation

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes MellitusNCT07303803 · 2026-01-01 · 1 site observation

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) MetastasesNCT07143045 · 2025-12-29 · 1 site observation

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate CancerNCT07363382 · 2025-12-20 · 1 site observation

SCAN Targeted Epidural Modulation for Parkinson's DiseaseNCT06919822 · 2025-12-08 · 1 site observation

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerNCT07217301 · 2025-11-26 · 2 site observations

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentNCT07467330 · 2025-11-15 · 1 site observation

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05 · 1 site observation

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08 · 2 site observations

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and GlecirasibNCT07164170 · 2025-09-22 · 1 site observation

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsNCT07169994 · 2025-09-02 · 1 site observation

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerNCT06868485 · 2025-08-18 · 1 site observation

Ozanimod in Patients With Alzheimer's DiseaseNCT06862960 · 2025-08-13 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05 · 1 site observation

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03 · 1 site observation

Taining Golden Lake Comprehensive Chronic Disease Management InitiativeNCT07308314 · 2025-08-01 · 1 site observation

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerNCT07047365 · 2025-07-25 · 1 site observation

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerNCT07008976 · 2025-07-07 · 1 site observation

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCNCT06855277 · 2025-07-01 · 1 site observation

PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary HypertensionNCT07131241 · 2025-06-27 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.